Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zacharon Pharmaceuticals Inc.

Division of BioMarin Pharmaceutical Inc.

Latest From Zacharon Pharmaceuticals Inc.

Licensing PARP Inhibitor A Win For BioMarin, Medivation

BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.

BioPharmaceutical Deals

Start-Up Quarterly Statistics, Q1 2013

Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.

BioPharmaceutical Medical Device

UPDATE: GSK and Avalon commit $495m to startups

GlaxoSmithKline will invest as much as $465 million to fund and potentially acquire 10 biotechnology startups founded by Avalon Ventures, which will give the venture capital firm up to a 13x return on its $30 million invested in the collaboration to back early-stage discovery platforms and drug candidates.

GSK and Avalon commit $495m to startups

In a deal meant to address the lack of funding for early-stage biotechnology companies, GlaxoSmithKline has committed up to $465 million, which will be combined with as much as $30 million from Avalon Ventures, to finance about 10 startups – and potential GSK acquisition targets – that will be headquartered in Avalon's home base of San Diego.

See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioMarin Pharmaceutical Inc.
  • Senior Management
  • Robin M Jackman, PhD, Pres. & CEO
    Douglas J Downs, CFO
    Charles A Glass, PhD, SVP, Res.
    Shripad S Bhagwat, PhD, CSO
  • Contact Info
  • Zacharon Pharmaceuticals Inc.
    Phone: (858) 459-9750
    5626 Oberlin Dr.
    Ste. 100
    San Diego , CA 92121